Skip to content
Open access

Broad genomic profiling, targeted therapy receipt, and overall survival among patients with metastatic non-squamous non-small cell lung cancer.

Oct 2026 · JCO Oncology Practice · 0 citations

Abstract

51 Background: Broad genomic profiling (BGP) is recommended for all patients with metastatic non-squamous NSCLC to guide targeted therapy (TT) selection. As actionable alterations and matched therapies continue to expand, BGP may identify a broader group of patients eligible for TT and consequently improve patients’ health outcomes. Whether BGP increases TT receipt and survival compared with biomarker-specific focused gene testing (FGT) remains unclear. Methods: We conducted a retrospective study of patients included in the SEER-Medicare database aged ≥66 years diagnosed with metastatic non-squamous NSCLC between 2017-2021. The exposure was pre-first line (1L) BGP vs. FGT identified using claims-based algorithms. The primary outcomes were 1L TT receipt, and 1L non-EGFR TT receipt. The secondary outcome was overall survival (OS) from 1L therapy initiation. We used inverse probability-weighted logistic regression for TT receipt and weighted Cox models for OS to adjust for baseline sociodemographic and clinical characteristics. To account for variation in the BGP-survival association across diagnosis years, we grouped years with similar survival patterns into three eras—2017–18, 2019, and 2020–21—estimated propensity scores within each era, and included interaction terms between testing type and era in all Cox models. Results: Among 4,378 patients, 2,532 (57.8%) received BGP and 1,846 (42.2%) received FGT. The proportion receiving BGP increased over time, from 499 (31.5%) in 2017-18, to 59.7% in 2019, and 1,433 (80.2%) in 2020-21. TT receipt and 1-year survival were numerically higher in 2021 than in 2017, but neither showed a significant linear trend across years: TT receipt, 16.0% to 18.2% (P for trend = .60); 1-year survival, 48.5% to 51.6% (P = .29). BGP was not significantly associated with 1L TT receipt overall (OR=1.13; 95% CI=0.95-1.36) but was associated with increased 1L non-EGFR TT receipt (OR=1.73; CI=1.24–2.45). BGP was not significantly associated with OS in the full sample (HR=0.92; CI=0.84-1.002). However, BGP was associated with lower mortality in 2017-18 (HR=0.80; CI=0.71-0.91), no significant association in 2019 (HR=0.88; CI=0.75-1.02), and higher mortality in 2020-21 (HR=1.19; CI=1.03-1.38). Additional adjustment for 1L TT receipt minimally changed estimates. Conclusions: In patients aged ≥66 years with metastatic NSCLC, pre-1L BGP was not associated with higher 1L TT receipt, but was associated with greater non-EGFR TT use. While there was no relation between BGP and OS in the full study period, there was heterogeneity in this association across time. This may reflect unmeasured confounding due to time-varying selection into BGP rather than a survival effect of testing. While BGP may improve access to TTs for less common actionable alterations, survival benefits may be difficult to detect in the overall tested population.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.